- Home
- NIC vs DNTH Comparison
NIC vs DNTH Comparison
Compare NIC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIC | DNTH |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NIC | DNTH |
|---|---|---|
| Price | $129.46 | $44.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $155.33 | $68.88 |
| AVG Volume (30 Days) | 152.5K | ★ 811.5K |
| Earning Date | 01-13-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | ★ 18.84 | N/A |
| EPS | ★ 9.34 | N/A |
| Revenue | ★ $375,962,000.00 | $3,078,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $39.22 | N/A |
| P/E Ratio | $14.07 | ★ N/A |
| Revenue Growth | ★ 9.68 | N/A |
| 52 Week Low | $97.90 | $13.37 |
| 52 Week High | $141.92 | $46.59 |
Technical Indicators
Market Signals| Indicator | NIC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 61.29 |
| Support Level | $122.84 | $42.37 |
| Resistance Level | $134.67 | $46.59 |
| Average True Range (ATR) | 3.38 | 2.71 |
| MACD | 0.78 | 0.62 |
| Stochastic Oscillator | 66.10 | 86.74 |
Price Performance
Historical ComparisonAbout NIC Nicolet Bankshares Inc.
Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.